Amgen published its 9th Biosimilars Trends Report, reporting on the current and future state of the US biosimilars market. Among Amgen’s findings were the following:
- Trends show an increase in savings per quarter, and in Q2 alone, savings in drug spend due to biosimilar availability are estimated to be $3.2 billion.
- Biosimilars primarily covered under the medical benefit have typically launched at a wholesale acquisition cost (WAC) that is generally 10% to 57% lower than that of the reference product.
- Seven or more launches of Humira® (adalimumab) biosimilars are possible in 2023. The entry of biosimilars is expected to lead to price declines across all products within the class.